The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders

Br J Haematol. 2021 Nov;195(3):338-351. doi: 10.1111/bjh.17766. Epub 2021 Aug 18.
No abstract available

Keywords: chronic myelomonocytic leukaemia; eosinophilia; mastocytosis; myelodysplastic/myeloproliferative neoplasms; myeloproliferative neoplasms.

Publication types

  • Practice Guideline

MeSH terms

  • Biological Products
  • Bone Marrow Examination
  • Calreticulin / genetics
  • Clone Cells
  • Disease Management
  • Exons / genetics
  • Forecasting
  • Genetic Testing*
  • Humans
  • Janus Kinase 2 / genetics
  • Molecular Diagnostic Techniques
  • Mutation, Missense
  • Myelodysplastic Syndromes / diagnosis*
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / pathology
  • Myeloproliferative Disorders / diagnosis*
  • Myeloproliferative Disorders / genetics
  • Myeloproliferative Disorders / pathology
  • Oncogene Proteins, Fusion / genetics
  • Point Mutation
  • Prognosis
  • Proto-Oncogene Proteins c-kit / genetics
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Receptors, Colony-Stimulating Factor / genetics
  • Receptors, Thrombopoietin / genetics
  • Severity of Illness Index
  • mRNA Cleavage and Polyadenylation Factors / genetics

Substances

  • Biological Products
  • CALR protein, human
  • CSF3R protein, human
  • Calreticulin
  • Oncogene Proteins, Fusion
  • Receptors, Colony-Stimulating Factor
  • Receptors, Thrombopoietin
  • mRNA Cleavage and Polyadenylation Factors
  • MPL protein, human
  • FIP1L1-PDGFRA fusion protein, human
  • KIT protein, human
  • Proto-Oncogene Proteins c-kit
  • Receptor, Platelet-Derived Growth Factor alpha
  • JAK2 protein, human
  • Janus Kinase 2